Outcomes Of Sustained-Release Formulation Of Valproate And Topiramate Monotherapy In Patients With Epilepsy: A Multi-Centre, Cohort Study
Yida Hu,Xishun Huang,Dinglie Shen,Meiping Ding,Hongbin Sun,Bin Peng,Xiangshu Hu,Hua Li,Kebin Zeng,Zhiqin Xi,Ying Zhang,Qingqing Cao,Jing Liu,Yan Zhou,Mengjiao Wu,Yaodong Lu,Guojun Chen,Xuefeng Wang
DOI: https://doi.org/10.1371/journal.pone.0047982
IF: 3.7
2012-01-01
PLoS ONE
Abstract:Background: New-generation antiepileptic drugs (AEDs) tend to replace traditional AEDs as the first-line choice for epilepsy. However, whether this change results in better outcome, especially in China, remains unknown.Methodology/Principal Findings: Two broad spectrum AEDs, the traditional drug of sustained-release formulation of valproate (SRVPA) and the new-generation drug of topiramate, were compared in patients with epilepsy as monotherapy in this multi-centre, observational cohort study from 2000 to 2011. The primary outcome was time to treatment failure. The secondary outcomes included time to first seizure, time to 12-month remission, and time to 24-month remission. Drug tolerability was assessed. Cox proportional hazard models (95% confidence interval [CI]) were used to analyse the relative risks expressed as hazard ratios (HR). Of the 1008 recruited patients, 519 received SRVPA and 489 received topiramate. SRVPA was better than topiramate (28.3% vs. 41.5%; HR = 0.62, [95% CI 0.49-0.77]; p<0.0001) in primary outcome, and in time to first seizure (56.1% vs. 69.3%; HR = 0.73, [95% CI 0.62-0.86]; p = 0.0002). No significant difference was observed between two groups in time to 12-month remission (52.6% vs. 42.5%; HR = 1.01, [95% CI 0.84-1.23]; p = 0.88) and time to 24-month remission (34.7% vs. 25.2%; HR = 1.11, [95% CI 0.88-1.42]; p = 0.38). 36 patients (6.9%) in SRVPA group and 37 patients (7.6%) in topiramate group presented treatment failure associated with intolerable adverse events, there was no significant difference between the two groups (p = 0.70).Conclusions: The SRVPA is more suitable than topiramate for Chinese epileptic patients, and our results support the viewpoint that traditional AEDs should be the first-line choice for epilepsy rather than new-generation AEDs. Citation: Hu Y, Huang X, Shen D, Ding M, Sun H, et al. (2012) Outcomes of Sustained-Release Formulation of Valproate and Topiramate Monotherapy in Patients with Epilepsy: A Multi-Centre, Cohort Study. PLoS ONE 7(12): e47982. doi: 10.1371/journal.pone.0047982